{"name":"Metro Infectious Disease Consultants","slug":"metro-infectious-disease-consultants","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CCP","genericName":"CCP","slug":"ccp","indication":"COVID-19 (acute infection, particularly in hospitalized or immunocompromised patients)","status":"marketed"}]}],"pipeline":[{"name":"CCP","genericName":"CCP","slug":"ccp","phase":"marketed","mechanism":"CCP is a convalescent plasma product that provides passive immunotherapy through antibodies from recovered COVID-19 patients to treat active SARS-CoV-2 infection.","indications":["COVID-19 (acute infection, particularly in hospitalized or immunocompromised patients)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOQXROekh4M1BwRERCdjQtS3dCTzU5NW05OThjTFVzU3FaeThOZHRnU2FDajJHemJMVmliaHpLZm9jNTJxQnQtWGlWVVpTVkx1R1hVS2puejdEcllVOURqb2FqNDRicklXb3RaMGhfM0xveWVFVGZ6cWdFQ2JBYy02MWZiWGFtZUhhdGpMV1pYTDFyNmkyWF9FdGtqUno3UEdkeXlwLWx5ZHRYcmQ0clFTV0dyTFRQUUtmLWpsOXRrUQ?oc=5","date":"2025-10-22","type":"trial","source":"Managed Healthcare Executive","summary":"Data From Two Rebyota Trials Show Quality of Life Improvements | IDWeek 2025 - Managed Healthcare Executive","headline":"Data From Two Rebyota Trials Show Quality of Life Improvements | IDWeek 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxPSERFbm5lSmtIRjhCbmVsdEVGcVRMZGlaWmhuaEVTa1ZOcXQwSUpTQllkWFpqSTdGanJwMUZ0czNsb3pzVDJ3bmFka2dCSzZjZGVpN0c5eWRYVkkwcXhnRE5Ndm5DMlBSOGZoYm1QanhocXptcFBVZkc5VEVkUUx0UXdQQkRIMVZFcS1CRnBVbzVEVF9UN2liWWZQNkU2bkI0TXpJUTJtZjJGOGd2Z1V1YVBQdDltRVFaRnhhVnNsVGMzbDNHc3pQWld0S2RxM3pkWW82eHZiMFBlVHd1STEyQVhwaXVkUEY3Z0psa3NaNTBaV0lqWHhfYVBTZFFWRnhGUXR3a21KaFNoSHJ6ZWFfcEoxc2pYc1hYNWNDb1p6VQ?oc=5","date":"2025-10-20","type":"trial","source":"BioSpace","summary":"Ferring Presents New Real-World REBYOTA® (fecal microbiota, live – jslm) Data Underscoring Effectiveness and Significant Improvements in Patient Quality of Life - BioSpace","headline":"Ferring Presents New Real-World REBYOTA® (fecal microbiota, live – jslm) Data Underscoring Effectiveness and Significant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQaXJWeWRfTFJOX3ZWcm15SnNnTHFkRi0yN08zaXJTdDIybTRIamZHT3cyYTNuSUt4cmstOW9rZzY2b05yOXo5UXM4UEdSZXU4VVdpYTFZa1lZTnA3eDNfYmkxbUk1a1B6aGRPOEktRS1xTHN1SjFqdGRaTDdnaVoxbkt2cnFTUQ?oc=5","date":"2021-03-19","type":"pipeline","source":"chicagotribune.com","summary":"Metro Infectious Disease Consultants - chicagotribune.com","headline":"Metro Infectious Disease Consultants","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}